Resources Repository
-
ArticlePublication 2016An Extended CEA of Schizophrenia Treatment in India under Universal Public Finance
This paper evaluates the potential health and financial risk protection effects of a policy of …
This paper evaluates the potential health and financial risk protection effects of a policy of universal public finance (UPF) to treating schizophrenia in India. The study uses the extended cost effectiveness analysis framework across income quintiles. The results show financial protection benefits concentrated in the richest income quintiles, while health gains were concentrated among the poorest. The value of insurance is highest for the poorest income and decreases as the household income increases. In settings…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Costing Methods | Health Systems | Clinical Care | Culture/Society | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2016UHC for Mental, Neurological, and Substance Use Disorders: An Extended CEA
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public …
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public finance (UPF) on epilepsy, schizophrenia, and depression in India and Ethiopia. The Ethiopian government has launched a National Mental Health Strategy which explicitly recognizes the importance of an efficient, equitable scale-up of mental health care within a broader, ongoing effort to increase levels of health insurance in the general population. The analyses show that enhanced coverage of effective treatment leads…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Social Determinants | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Benefit-Cost Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Global -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Cost-Effectiveness Analysis | Mental Health | Priority Setting/Ethics | Costing Methods | Mathematical Models | State-Transition | Microsimulation | Decision Analysis | Chronic Disease/Risk | Health/Medicine | Latin America & Caribbean -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Cost-Effectiveness Analysis | Mental Health | Preferences/Values | Health Outcomes | Evidence Synthesis | Technology Assessment | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Health/Medicine | North America -
ArticlePublication 2011Cost-Effectiveness of Psychotherapy for Cluster C Personality Disorders
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model …
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model that compares the cost-effectiveness of five treatment modalities (long-term outpatient psychotherapy, short-term and long-term day hospital psychotherapy, and short-term and long-term inpatient psychotherapy) for patients with cluster C personality disorders. The analyses are conducted from the societal and payer perspectives. Patient-level data comes from 466 patients with cluster C personality disorders who were admitted to 6 specialist centers of psychotherapy…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Health/Medicine | Europe -
ArticlePublication 2010Cost-Effectiveness of Psychotherapy for Cluster B Personality Disorders
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model …
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model that compares the cost-effectiveness of three treatment strategies (outpatient, day-hospital and inpatient psychotherapy) for patients with cluster B personality disorders. Patient-level data is used to populate the model and the analyses are conducted from the societal and payer perspectives. From the societal perspective, the findings show that the incremental cost-effectiveness ratio (ICER) of day hospital psychotherapy compared to outpatient psychotherapy…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Health/Medicine | Europe